Arianna Paris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Arianna Paris has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Gabriela Grimaldi
Department of Ophthalmology, Institute of Clinical Neurosciences of Southern Switzerland (INSI), Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland
2 shared publications Alex Casanova
Ophthalmology, Institute of Clinical Neurosciences of Southern Switzerland (INSI), Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland
1 shared publication- Andreas Ebneter
University of Bern Bern Switzerland
1 shared publication - Andreas Weinberger Rosen
Department of Ophthalmology, RWTH Aachen University, 52074 Aachen, Germany
1 shared publication Aude Ambresin
Swiss Visio Montchoisi, 1006 Lausanne, Switzerland. Swiss Visio Retina Research Center, 1006 Lausanne, Switzerland
1 shared publicationBahram Bodaghi
Department of Ophthalmology, Pitié-Salpêtrière University Hospital, Sorbonne Université, Paris, France
1 shared publication
Latest Publications
- 3 July 2026
- Published by Springer Nature in Eye
- Vol. 40 (14) , 2187-2192
Long-term follow-up and outcomes of a Diabetic Eye Screening Programme in patients aged 80 with no diabetic eye disease at baseline: should we be routinely screening this cohort?
It remains unclear whether routine annual diabetic eye screening is still warranted for individuals aged 80 and over who show no signs of retinopathy at baseline. This study aimed to determine the incidence of referable diabetic retinopathy (DR) or diabetic maculopathy in individuals aged 80 years and older with no retinopathy at baseline in the South East London NHS Diabetic Eye Screening Programme (DESP), and to estimate the proportion requiring treatment. Data from the South East London DESP were linked with Hospital Eye Service (HES) records from 2009 to 2025. Individuals aged 80 years during 2009-2014 with no diabetic retinopathy or maculopathy (R0M0) at baseline and at least five years of follow-up were included. Screening and hospital data were analysed to determine referrals, diagnoses and treatments. Of 3599 eligible participants, 3258 (90.5%) had no referable diabetic retinopathy or diabetic maculopathy at final screening. In total, 532 (14.8%) were referred to HES, mainly for non-diabetic causes (56.6%). Referrals for sight-threatening diabetic retinopathy accounted for 89 cases (2.5%), and only four individuals (0.11%) required treatment, all for diabetic macular oedema. No cases of proliferative diabetic retinopathy were identified. Among people aged 80 years and older without diabetic retinopathy at baseline, the incidence of sight-threatening disease and treatment need were extremely low. Routine DESP recall in this population may offer limited clinical benefit and should be reconsidered within a risk-stratified screening framework.
- 3 July 2026
- Published by Springer Nature in Eye
- Vol. 40 (14) , 2187-2192
Long-term follow-up and outcomes of a Diabetic Eye Screening Programme in patients aged 80 with no diabetic eye disease at baseline: should we be routinely screening this cohort?
It remains unclear whether routine annual diabetic eye screening is still warranted for individuals aged 80 and over who show no signs of retinopathy at baseline. This study aimed to determine the incidence of referable diabetic retinopathy (DR) or diabetic maculopathy in individuals aged 80 years and older with no retinopathy at baseline in the South East London NHS Diabetic Eye Screening Programme (DESP), and to estimate the proportion requiring treatment. Data from the South East London DESP were linked with Hospital Eye Service (HES) records from 2009 to 2025. Individuals aged 80 years during 2009-2014 with no diabetic retinopathy or maculopathy (R0M0) at baseline and at least five years of follow-up were included. Screening and hospital data were analysed to determine referrals, diagnoses and treatments. Of 3599 eligible participants, 3258 (90.5%) had no referable diabetic retinopathy or diabetic maculopathy at final screening. In total, 532 (14.8%) were referred to HES, mainly for non-diabetic causes (56.6%). Referrals for sight-threatening diabetic retinopathy accounted for 89 cases (2.5%), and only four individuals (0.11%) required treatment, all for diabetic macular oedema. No cases of proliferative diabetic retinopathy were identified. Among people aged 80 years and older without diabetic retinopathy at baseline, the incidence of sight-threatening disease and treatment need were extremely low. Routine DESP recall in this population may offer limited clinical benefit and should be reconsidered within a risk-stratified screening framework.
- Open Access
- 25 March 2025
- Published by Elsevier in Ophthalmology Retina
- Vol. 9 (9) , 838-847
One-Year Outcomes after Switching to Faricimab in Eyes with Pretreated Neovascular Age-Related Macular Degeneration
- 25 March 2025
- Published by Elsevier in Ophthalmology Retina
- Vol. 9 (9) , 838-847
Open AccessOne-Year Outcomes after Switching to Faricimab in Eyes with Pretreated Neovascular Age-Related Macular Degeneration
- Open Access
- 12 November 2024
- Published by BMJ in British Journal of Ophthalmology
- Vol. 109 (5) , 600-605
Short-term intraocular pressure changes after intravitreal aflibercept 2 mg, aflibercept 8 mg and faricimab: a prospective, comparative study
Background/aims Intravitreal injection (IVT) of anti-vascular endothelial growth factor agents is the standard of care for several retinal diseases but can cause intraocular pressure (IOP) elevations. This study investigates short-term postinjection IOP changes following aflibercept 8 mg and faricimab, compared with aflibercept 2 mg. Methods This observational, prospective study included 90 patients with age-related macular degeneration or diabetic macular oedema, divided into three groups, receiving aflibercept 2 mg, aflibercept 8 mg or faricimab. IOP was measured using an iCare IC200-tonometer preinjection (T0) and at 30 s (T1), 5 min (T2) and 15 min (T3) postinjection. Primary outcomes included IOP changes at the four time points within and between treatment groups. The incidence of transient visual loss requiring paracentesis was recorded. Results All groups experienced a significant IOP increase at T1, with mean IOP increase being 41.47±12.95 mm Hg for aflibercept 2 mg, 43.46±8.97 mm Hg for aflibercept 8 mg and 32.19±11.06 mm Hg for faricimab. By T2, IOP differences were not significant, and by T3, mean IOP returned within normal limits across all groups. Faricimab showed a smaller initial IOP spike than both aflibercept formulations, but this difference was not statistically significant at T2 and T3. Conclusion Transient IOP spikes are observed post-IVT of aflibercept 8 mg and faricimab, with similar trends to aflibercept 2 mg. The initial IOP elevation normalised within 15 min. Faricimab had a lower initial spike, but overall IOP profiles were comparable across different agents.
- 12 November 2024
- Published by BMJ in British Journal of Ophthalmology
- Vol. 109 (5) , 600-605
Open AccessShort-term intraocular pressure changes after intravitreal aflibercept 2 mg, aflibercept 8 mg and faricimab: a prospective, comparative study
Background/aims Intravitreal injection (IVT) of anti-vascular endothelial growth factor agents is the standard of care for several retinal diseases but can cause intraocular pressure (IOP) elevations. This study investigates short-term postinjection IOP changes following aflibercept 8 mg and faricimab, compared with aflibercept 2 mg. Methods This observational, prospective study included 90 patients with age-related macular degeneration or diabetic macular oedema, divided into three groups, receiving aflibercept 2 mg, aflibercept 8 mg or faricimab. IOP was measured using an iCare IC200-tonometer preinjection (T0) and at 30 s (T1), 5 min (T2) and 15 min (T3) postinjection. Primary outcomes included IOP changes at the four time points within and between treatment groups. The incidence of transient visual loss requiring paracentesis was recorded. Results All groups experienced a significant IOP increase at T1, with mean IOP increase being 41.47±12.95 mm Hg for aflibercept 2 mg, 43.46±8.97 mm Hg for aflibercept 8 mg and 32.19±11.06 mm Hg for faricimab. By T2, IOP differences were not significant, and by T3, mean IOP returned within normal limits across all groups. Faricimab showed a smaller initial IOP spike than both aflibercept formulations, but this difference was not statistically significant at T2 and T3. Conclusion Transient IOP spikes are observed post-IVT of aflibercept 8 mg and faricimab, with similar trends to aflibercept 2 mg. The initial IOP elevation normalised within 15 min. Faricimab had a lower initial spike, but overall IOP profiles were comparable across different agents.
- 12 December 2023
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 34 (3) , NP66-NP71
Pan fibroblast growth factor receptor inhibitor associated retinopathy
Purpose: To report a case of Fibroblast Growth Factor Receptor inhibitor (FGFRi) associated retinopathy in a patient treated with Erdafitinib. Case report: A patient with a history of non-muscle invasive urothelial carcinoma treated with Erdafitinib developed symptomatic unifocal bilateral serous retinal detachments (SRD) eight weeks after starting this new treatment. Six months after discontinuing the drug, the SRDs resolved and visual acuity recovered to baseline. However, hyper and hypo auto fluorescent lesions were still visible on fundus autofluorescence, suggesting a still ongoing retinal pigment epithelium (RPE) impairment. Conclusions: Cancer treatments using FGFRi are showing promising results but their ocular toxicity is not well reported nor fully understood. Oncologists should be aware of the potential risks associated with FGFRi and involve ophthalmologists for the follow-up of their patients. The toxicity of FGFRi seems to resolve after drug continuation, but a certain degree of infra clinical RPE impairment may persist. Longer term follow-ups are warranted to further understand the effects of FGFRi on the RPE.
- 12 December 2023
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 34 (3) , NP66-NP71
Pan fibroblast growth factor receptor inhibitor associated retinopathy
Purpose: To report a case of Fibroblast Growth Factor Receptor inhibitor (FGFRi) associated retinopathy in a patient treated with Erdafitinib. Case report: A patient with a history of non-muscle invasive urothelial carcinoma treated with Erdafitinib developed symptomatic unifocal bilateral serous retinal detachments (SRD) eight weeks after starting this new treatment. Six months after discontinuing the drug, the SRDs resolved and visual acuity recovered to baseline. However, hyper and hypo auto fluorescent lesions were still visible on fundus autofluorescence, suggesting a still ongoing retinal pigment epithelium (RPE) impairment. Conclusions: Cancer treatments using FGFRi are showing promising results but their ocular toxicity is not well reported nor fully understood. Oncologists should be aware of the potential risks associated with FGFRi and involve ophthalmologists for the follow-up of their patients. The toxicity of FGFRi seems to resolve after drug continuation, but a certain degree of infra clinical RPE impairment may persist. Longer term follow-ups are warranted to further understand the effects of FGFRi on the RPE.